An open-label phase 2 trial of talabostat and gemcitabine [gemzar; Eli Lilly] in patients with stage IV adenocarcinoma of the pancreas
Phase of Trial: Phase II
Latest Information Update: 07 Jun 2007
At a glance
- Drugs Gemcitabine; Talabostat
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 07 Jun 2007 Status change from in progress to discontinued.
- 24 Jan 2007 Status change
- 08 Nov 2005 New trial record.